Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo ...
Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a ...
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
5 days ago · Alteogen will receive an upfront payment of $20 million, with another $280 million on offer from Daiichi Sankyo if the new formulation of Enhertu (trastuzumab deruxtecan) makes it to market and ...
Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In ...
3 days ago · (RTTNews) - Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the deal, Daiichi Sankyo will acquire world-wide rights ...
Alteogen enters into an Exclusive License Agreement to Develop …
3 days ago · DAEJEON, South Korea, Nov. 11, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilizing Hybrozyme™ Technology, to develop and commercialize a ...
Daiichi Sankyo links up with Korea's Alteogen on subcutaneous …
5 days ago · Under the deal, Daiichi will pay Alteogen $20 million upfront to develop the subcutaneous (SC) Enhertu formulation using its human hyaluronidase (ALT-B4) platform, according to a Korean exchange ...
알테오젠 – 알테오젠
News. Alteogen announces amendment to license agreement with MSD. Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile. Hyaluronidase : A new way to be excluded from drug price negotiations under IRA. Merck to Manufacture Next-Generation Biotherapeutics for Alteogen.
Altos Biologics Files for Approval of Aflibercept Biosimilar - PR …
Jul 2, 2024 · Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively.
Alteogen Enters Into an Exclusive License Agreement to Develop …
Jan 2, 2023 · Under the terms of the agreement, Sandoz will acquire the world-wide rights to use ALT-B4, Alteogen’s novel hyaluronidase derived utilizing Hybrozyme™ Technology, to develop and...
Alteogen signs global licence deal with Sandoz - Pharmaceutical …
Jan 3, 2023 · Alteogen, a South Korean biotech company, has signed an exclusive deal with Sandoz to develop and market biosimilar products using its novel hyaluronidase enzyme, ALT-B4. Sandoz will have global rights to use ALT-B4 and option to …
- Some results have been removed